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Abstract
Data driven computational approaches to predicting protein-ligand binding are
currently achieving unprecedented levels of accuracy on held-out test data sets.
Up until now, however, this has not led to corresponding breakthroughs in
our ability to design novel ligands for protein targets of interest. This review
summarizes the current state of the art in this field, emphasizing the recent
development of deep neural networks for predicting protein-ligand binding. We
explain the major technical challenges that have caused difficulty with predicting
novel ligands, including the problems of sampling noise and the challenge of
using benchmark datasets that are sufficiently unbiased that they allow the
model to extrapolate to new regimes.
Introduction
Molecular recognition is a fundamental requirement of biological systems.
The interactions between proteins and small molecules are central to biology,
allowing cells to sense their surroundings and respond appropriately. Estimates
place the number of small molecules that can be synthesized at ≈ 1060, yet5
just a small fraction of potential protein-ligand interactions have been explored.
Finding novel interactions is of great importance to drug discovery and basic
biology. Given the enormity of the search space, computational approaches can
narrow down the possibilities. However, despite three decades of computational
effort, biochemical experiments are still essential to determine the efficacy of10
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ligand binding to a protein target [1, 2]. The results of computational anal-
ysis have been decidedly mixed: it is challenging to use even experimentally
well-characterized ligand protein interactions to computationally design novel
interactions [1, 2], much less explore the vast space of possibilities.
There are three increasingly demanding tasks in protein-ligand binding pre-15
diction: virtual screening predicts whether a ligand binds to a given target;
affinity prediction predicts the binding affinity; and pose prediction identifies
the molecular interactions causing binding to occur. In this review we focus on
the first; the others have been reviewed elsewhere [3, 4]. Approaches to virtual
screening can be categorised as physical or statistical. The idea of using first20
principles physical models to describe protein-ligand interactions is attractive,
however timescale and computational resource constraints mean that simplified
descriptions of features such as protein flexibility, and solvent are necessary.
Even the most sophisticated docking algorithms cannot accurately reproduce
large numbers of known interactions, much less predict new ones. Scoring func-25
tions can be empirical [5, 6, 7, 8, 9] or knowledge-based [10, 11, 12, 13, 14].
Significant expertise is required to encode physico-chemical interactions through
the use of hand-tuned features and parameters, and can be highly specific to
the system that they are designed for [15].
Recently, the use of high throughput methods to screen large libraries of30
proteins and small molecules and quantify their interactions has made it possi-
ble to correlate activity with representations of proteins and small molecules, to
infer predictive models. Techniques from machine learning and artificial intel-
ligence have been introduced, allowing both the parameters and the model to
be learned from the wealth of experimental data available in databases such as35
Chembl [16, 17, 18, 19]. Increasingly publications are demonstrating that data
driven approaches have the potential to make significant contributions to these
problems [20**, 21*, 22*, 23*] [24, 25, 26, 27].
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Machine learning - potential and limitations
The aim of any machine learning or statistical approach is to identify pat-40
terns among training examples that can be used to make predictions outside the
training set. An algorithm achieves this by mapping the training set representa-
tion to a space in which active and inactive ligands segregate - this mapping can
be guided by physical models [13][23*] but is more often learned directly from the
data without addition of extensive physico-chemical knowledge [21*, 22*][26].45
Once this mapping has been learned, it is hoped that the location of new ex-
amples in this space - clustered with training set actives or inactives - will
accurately predict their activity. To compare the performance of different algo-
rithms, a test set of ligands with known activity is held-out during the training
process. An algorithm that can make accurate predictions for this unseen data50
is presumed to extrapolate well.
In particular, approaches that use deep neural networks (DNNs) have been
shown to make predictions on held-out test sets with eye-opening levels of ac-
curacy, exceeding 0.95 AUC (Area under the Receiver Operator Characteristic)
on benchmark datasets [28][22*]. However, the extent to which such results55
extrapolate is not yet clear - are they overfit to the training data [29, 1][30**]?
A number of studies posit that the test/train protocol is not as exacting as it
might appear due to the non-uniformity of the distribution of ligands in chemi-
cal space. If training set actives are closer to test set actives than to training set
inactives, by some metric that is not fully predictive of protein-ligand binding60
activity such as molecular weight, or number of ring systems, then the algo-
rithm can appear to make accurate predictions for test set molecules without
being able to extrapolate this predictive ability [31, 19, 32]. Machine learning
performs best when abundant data drawn uniformly from the space of interest
is available, but in this setting human chemists choose which molecules to work65
with, often based on clear similarities to known success stories [33, 34].
Definitively showing that these approaches generalise is perhaps the out-
standing challenge facing this field today. In the search for novel pharmaceu-
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Figure 1: Schematic of a deep neural network for predicting properties of small
molecule ligands. In this schematic, the input molecule is first encoded in a binary molecular
fingerprint of fixed length. Convolutional architectures are a popular choice among practi-
tioners and typically require that a fixed length representation be either used or learned from
the molecular graph. The neural network simply consists of a very large number of simple
functions (or neurons) of the form indicated in the schematic. Deep neural networks have
large numbers of layers of neurons, resulting in a huge number of parameters that are learnt
during training from the data, which is typically split into distinct training, cross-validation
and test datasets.
ticals, the ability to predict the binding of ligands that are chemically distinct
from those in the training data is highly valuable, but much more challenging for70
algorithms that are expert at identifying patterns among training set ligands.
The goal of this article is to review statistical approaches to molecular recog-
nition in the context of protein-ligand binding, focusing on recent results that
exploit DNNs (see figure 1). Here we briefly outline the basic steps of machine
learning algorithm that predicts protein-ligand binding.75
4
Molecular Representation
There are almost as many choices for representation of the input data as there
are for the machine learning algorithm employed [35, 36]. The simplest involve
counting the numbers of different heavy atoms present in a ligand, together with
other features such as hydrogen bond donors/acceptors, chiral centers and ring80
systems [19][30**]. Some information about the chemical structure is retained
by descriptors such as atom pairs or donor-acceptor pairs [37, 38] where each
element has the form (atom type i) - (distance in bonds) - (atom type j).
More information is encoded by chemical fingerprints, for example MACCS
keys [39] and ECFP fingerprints [40]; fixed length binary descriptors which can85
be generated by the package RDKit [41]. Here, each non-hydrogen atom is used
as a centre from which fragments are generated by extending radially from the
centre along bonds to neighbouring atoms; the maximum radius considered N
is encoded in the name as ECFP2N . A unique identifier is assigned to each
fragment, and the set of identifiers for a molecules is mapped to a fixed length90
bit vector to yield the molecular fingerprint.
This abundance raises the question of which representation is most useful
for different prediction tasks. Recently the suggestion has been made that it
may be more effective to also learn the molecular representation itself, alongside
the metric and corresponding embedding space used to distinguish active from95
inactive ligands [21*, 22*][27, 42]. However, counter-intuitively it has also been
reported that the use of more complex molecular descriptors can result in little
gain of predictive ability [43][30**]
Representation and Sampling Noise
One rational for the finding that more complex representations can result100
in little improvement is noise due to finite sampling. The basic premise of any
predictive algorithm is that similarities among known interaction partners can
reveal the requirements of the binding site, and thus predict novel interactions.
A straightforward approach is to compile the set of ligands known to bind to a
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protein receptor of interest, and identify those features that show statistically105
significant enrichment among this set [44]. However, because there are only
finitely many samples (i.e. known ligand binders), some features will be enriched
purely by chance. This chance similarity increases with the number of variables,
so representations that have more variables will lead to greater random similarity
between features. For DNNs in particular, representations with thousands or110
even millions of features have recently been employed [24][21*, 22*]; although
these algorithms have the ability to share information between targets it is
still important that the level of chance similarity between small molecules is
quantified and accounted for.
This phenomena has been carefully studied in the field of random matrix115
theory, which provides a null distribution that describes the similarity between
samples (ligands) that can be expected by chance due to finite sampling as
a function of the number of samples available, and the number of variables
present in the ligand descriptor [45][46*]. A simpler method for generating this
null distribution simply involves computing the covariance matrices of multiple120
sets of n random ligands, where n is the sample size, using the same ligand
descriptor for each set, and so obtaining the distribution of the largest entries
that occur due to finite sampling noise. A similar approach can be taken for
any measure of molecular similarity, defining a statistical null distribution with
which to compare putative active molecules.125
Benchmark Datasets
The application of machine learning algorithms to problems such as protein-
ligand binding is facilitated by the availability of large experimental datasets.
For both algorithms that require 3D complexes and those that work with 2D
ligand structures, a number of benchmark datasets have emerged that allow130
researchers to compare the performance of different algorithms. The PDB-
bind benchmark [47] comprises 1300 diverse protein-ligand complexes with high
quality structural and binding data. Another popular choice is the Directory
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of Useful Decoys (DUD) [48] or Directory of Useful Decoys Enhanced (DUDE)
benchmark [18], which have been carefully constructed to attempt to control135
for dataset biases that enable a machine learning algorithm to learn features
that distinguish actives from inactives without providing information about
the relevant molecular interaction. The construction of benchmark datasets
that are unbiased, and so provide an accurate indication of how well an algo-
rithm can extrapolate is an important research direction that requires atten-140
tion [49*][50][30**].
Choice of Algorithm
Early linear regression methods were soon super-seeded by nonlinear models
constructed using early versions of neural networks, among other techniques.
Algorithms such as support vector machines [51, 52], Gaussian Procceses [53, 54]145
and Random Forests (RF) [55, 15, 56, 43] have all received significant attention
within the community. One advantage of these approaches is that many allow
some level of interpretability, enabling the medicinal chemist to rationalise and
evaluate the resulting model. This is more challenging for DNNs (see figure 1),
which have recently been found to be highly successful on a variety of different150
tasks including computer vision [57] and speech recognition [58]. In the last few
years there has been a burst of activity involving the construction of DNNs to
predict protein-ligand binding [20**, 21*, 22*] [24, 25, 26, 28, 59, 60, 61, 62].
A key breakthrough came in 2012 with the Merck sponsored Kaggle contest,
in which the winning entry submitted by G. Dahl improved the mean squared155
Pearson correlation coefficient (R2) between predicted and observed binding
activities over 15 proprietary Merck datasets from 0.42 (attained using RFs)
to 0.49 [20**]. Although a combination of DNNs [63*], gradient boosting ma-
chine [64] and Gaussian process regression [53] were used by the winning entry,
Dahl suggests that the DNN was the main cause of the performance increase.160
A careful comparison of DNNs and RFs at protein-binding prediction over 15
datasets found that the best R2 values over all parameter sets are obtained
7
using DNNs for five datasets, and using RFs for one, with mixed results for
the remaining datasets. For refined parameter ranges, this increased to nine
datasets for DNNs compared to one for RFs , leading the authors to conclude165
that DNNs have the potential to outperform RFs generally [20**].
A crucial issue with DNNs is the set of algorithmic parameters affecting pre-
dictive performance that must be decided by the researcher, such as network
size, choice of activation functions and use of dropout [65], which are distinct
from parameters that are learned from the data. In general it is not computa-170
tionally feasible to search the space of parameter values, in particular because
different parameters are not independent of each other. Some analysis has been
presented by varying one parameter at a time, and recording the R2 values of
the resulting DNNs [20**].
Conclusion175
Advances in technology have led to enormous opportunity for using ma-
chine learning algorithms to learn models of protein ligand interactions. Ma-
chine learning algorithms are inherently flexible and with a sufficient amount
of carefully curated data, the algorithms have the potential to find patterns
that humans cannot find on their own. However, besides the issues already180
discussed with this review, other challenges must be overcome: the parameters
learned from the data can lead to overfitting - the unintended specialisation of
the trained model to the dataset used for training. For example, if the training
and test datasets were identical, the algorithm would simply memorise all de-
tails of the training data, and achieve perfect performance on the test dataset.185
However, it would likely be unable to make accurate predictions for additional
molecules that it had not previously seen before.
For chemical data, a key problem is to define what constitutes a distinct
partitioning between test and training data. Simply requiring that the molecules
are different from one another is not enough [31, 19, 32][30**]. Machine learning190
algorithms are extremely effective at learning any feature that distinguishes
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samples from different classes (such as binding and non-binding). This means
that it is necessary to go further, and require that active molecules do not
share any nuisance similarity or property that distinguishes them from inactive
molecules, while not being the crucial molecular feature that enables binding.195
The situation is complicated by the fact that in most cases the crucial feature
that enables binding is not known - indeed identifying these feature(s) is the
ultimate goal of the exercise. However relatively simple devices such as synthetic
datasets, in which binding is said to occur if particular logical combinations of
features are present, or bias measures that quantify simple molecular similarities200
can be surprisingly effective.
Despite these challenges, this is an exciting time for building models of
protein-ligand interactions. One could hope that a review written five years
hence would be filled more with victories than warnings.
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